GSK plc (LON:GSK)
2,028.00
+12.00 (0.60%)
Apr 28, 2026, 4:57 PM GMT
GSK plc Employees
GSK plc had 66,841 employees as of December 31, 2025. The number of employees decreased by 1,788 or -2.61% compared to the previous year.
Employees
66,841
Change (1Y)
-1,788
Growth (1Y)
-2.61%
Revenue / Employee
488.73K GBP
Profits / Employee
85.52K GBP
Market Cap
80.96B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66,841 | -1,788 | -2.61% |
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 96,100 |
| Haleon | 24,535 |
| Smith & Nephew | 16,988 |
| Convatec Group | 10,910 |
| Hikma Pharmaceuticals | 9,400 |
| HUTCHMED (China) | 1,796 |
| Genus | 3,190 |
| Oxford Nanopore Technologies | 1,335 |
GSK plc News
- 6 hours ago - GSK to Report Q1 Earnings with Strong Revenue Expectations - GuruFocus
- 12 hours ago - GSK Receives FDA Priority Review for Bepirovirsen in Chronic Hepatitis B Treatment - GuruFocus
- 13 hours ago - FDA Accepts Priority Review And Grants BT Designation For Bepirovirsen In Chronic Hepatitis B - Nasdaq
- 13 hours ago - GSK Receives Fast-Track Review for New Hepatitis B Treatment - GuruFocus
- 1 day ago - GSK Secures Breakthrough Therapy Designation for Efimosfermin - GuruFocus
- 1 day ago - GSK Faces Court Ruling Favoring TESARO in Dispute - GuruFocus
- 1 day ago - GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute - GuruFocus
- 4 days ago - GSK Faces Legal Setback as AnaptysBio Wins Court Ruling - GuruFocus